No Data
Fanpepp --- In the fiscal year ending December 2024, research and development will be advanced focusing on antibody-inducing peptide projects and functional peptides.
Fanpep Co., Ltd. <4881> announced its consolidated financial results for the fiscal year ending December 2024 on the 12th. Revenue was 0.006 billion yen (compared to 0 billion yen in the previous period), operating loss was 0.901 billion yen (compared to 0.994 billion yen in loss), ordinary loss was 0.896 billion yen (compared to 0.94 billion yen in loss), and net loss attributable to the Shareholder for the current period was 0.889 billion yen (compared to 0.933 billion yen in loss). In the antibody-inducing peptide project, the antibody-inducing peptide "FPP003" (target protein: IL-17A) is discussed.
Fanpep - Submission of the clinical trial plan for the start of the allergy Vaccine clinical trial.
Fanpep <4881> announced on the 12th that it has submitted the clinical trial plan for the allergy Vaccine (antibody-inducing peptide FPP004X) being developed for allergic rhinitis to the Pharmaceuticals and Medical Devices Agency (PMDA). The Phase 1 clinical trial is scheduled to begin as soon as the PMDA completes its necessary investigation. The antibody-inducing peptide FPP004X induces the production of antibodies against IgE (Immunoglobulin E) in the body to treat.
It seems strong and there is a strong desire to explore, but the upward movement might be heavy.
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to show a stable development. In the US stock market on the 12th, the Dow Inc fell by $225.09 (-0.50%) to $44,368.56, marking a retreat after three days. As the Consumer Price Index (CPI) unexpectedly accelerated, expectations for interest rate cuts diminished, causing interest rates to rise, which weighed on stock prices. On the other hand, the Nasdaq saw an increase propelled by Intel (INTC) and Apple (AAPL), recovering into positive territory, while the major Index ETF closed mixed.
Randix, Collabos, etc.
＜2981＞Randix announces an increase in dividends, the year-end dividend per share is 78.00 yen, revised upward from 75.00 yen, with an operating profit forecast for the current period of 2.13 billion yen, revised from 1.75 billion yen. <3695＞GMO-R & AI introduces a shareholder benefit program. <3908＞Collaboros is conducting an off-market sale of 0.17 million 3600 shares. <4263＞Sasmido is collaborating with Asuka Pharmaceutical for joint research and development. <4316＞Bimap revises downward, forecasting an operating loss of -0.17 billion yen, revised from 0.05 billion yen. <4374＞Robopay announces an increase in dividends, the year-end dividend per share from the previous period.
FunPep FY Loss Y889.00M Vs Loss Y933.00M
FunPep: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (consolidated)